Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF - PubMed (original) (raw)
doi: 10.1016/j.ymthe.2006.05.008.
J Y Oh, B H Park, D E Lee, J S Kim, H E Park, M S Roh, J E Je, J H Yoon, S H Thorne, D Kirn, T H Hwang
Affiliations
- PMID: 16905462
- DOI: 10.1016/j.ymthe.2006.05.008
Free article
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF
J H Kim et al. Mol Ther. 2006 Sep.
Free article
Abstract
Targeted oncolytic viruses and immunostimulatory therapeutics are being developed as novel cancer treatment platforms. These approaches can be combined through the expression of immunostimulatory cytokines from targeted viruses, including adenoviruses and herpesviruses. Although intratumoral injection of such viruses has been associated with tumor growth inhibition, eradication of distant metastases was not reported. The major limitations for this approach to date have been (1) inefficient intravenous virus delivery to tumors and (2) the lack of predictive, immunocompetent preclinical models. To overcome these hurdles, we developed JX-594, a targeted, thymidine kinase(-) vaccinia virus expressing human GM-CSF (hGM-CSF), for intravenous (i.v.) delivery. We evaluated two immunocompetent liver tumor models: a rabbit model with reproducible, time-dependent metastases to the lungs and a carcinogen-induced rat liver cancer model. Intravenous JX-594 was well tolerated and had highly significant efficacy, including complete responses, against intrahepatic primary tumors in both models. In addition, whereas lung metastases developed in all control rabbits, none of the i.v. JX-594-treated rabbits developed detectable metastases. Tumor-specific virus replication and gene expression, systemically detectable levels of hGM-CSF, and tumor-infiltrating CTLs were also demonstrated. JX-594 holds promise as an i.v.-delivered, targeted virotherapeutic. These two tumor models hold promise for the optimization of this approach.
Comment in
- A pox on your tumor.
Williams DA. Williams DA. Mol Ther. 2006 Sep;14(3):313. doi: 10.1016/j.ymthe.2006.07.002. Epub 2006 Jul 17. Mol Ther. 2006. PMID: 16844420 No abstract available.
Similar articles
- Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH. Lee JH, et al. Cancer Gene Ther. 2010 Feb;17(2):73-9. doi: 10.1038/cgt.2009.50. Epub 2009 Jul 24. Cancer Gene Ther. 2010. PMID: 19629143 Free PMC article. - Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. Thorne SH, et al. J Clin Invest. 2007 Nov;117(11):3350-8. doi: 10.1172/JCI32727. J Clin Invest. 2007. PMID: 17965776 Free PMC article. - Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Park BH, et al. Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Lancet Oncol. 2008. PMID: 18495536 Clinical Trial. - JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Merrick AE, Ilett EJ, Melcher AA. Merrick AE, et al. Curr Opin Investig Drugs. 2009 Dec;10(12):1372-82. Curr Opin Investig Drugs. 2009. PMID: 19943208 Review. - Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ, Thorne SH, Bell JC, Kirn DH. Breitbach CJ, et al. Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. doi: 10.2174/138920112800958922. Curr Pharm Biotechnol. 2012. PMID: 21740365 Review.
Cited by
- Treatment of Liver Cancer.
Liu CY, Chen KF, Chen PJ. Liu CY, et al. Cold Spring Harb Perspect Med. 2015 Jul 17;5(9):a021535. doi: 10.1101/cshperspect.a021535. Cold Spring Harb Perspect Med. 2015. PMID: 26187874 Free PMC article. Review. - Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy.
Liu X, Zhao J, Li X, Lao F, Fang M. Liu X, et al. Vaccines (Basel). 2022 Sep 17;10(9):1552. doi: 10.3390/vaccines10091552. Vaccines (Basel). 2022. PMID: 36146629 Free PMC article. Review. - The evolution of poxvirus vaccines.
Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. Sánchez-Sampedro L, et al. Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726. Viruses. 2015. PMID: 25853483 Free PMC article. Review. - Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review. - Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, Patt R, Pelusio A, Burke J, Hwang TH, Kirn D, Park YS. Park SH, et al. Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Mol Ther. 2015. PMID: 26073886 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical